Wockhardt secures approval from CDSCO for Miqnaf

03 Jan 2025 Evaluate

Wockhardt has received an approval from the Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) for Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults. Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP including those caused by multi-drug resistant (MDR) pathogens. The approval follows a favourable recommendation for manufacture and marketing of Nafithromycin from the Subject Expert Committee (SEC) of CDSCO.

Wockhardt plans to launch Miqnaf in the Indian market in coming few months. Over the period of 25 years, Wockhardt has focused its drug discovery efforts in the area of discovering novel antibiotics for multi-drug resistant infections. This has resulted in a portfolio of 6 products at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA.

Wockhardt is a research based Global Pharmaceutical and Biotech company.


Wockhardt Share Price

1418.45 -20.90 (-1.45%)
03-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1770.10
Dr. Reddys Lab 1151.25
Cipla 1495.15
Lupin 2094.50
Zydus Lifesciences 901.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...